de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Contact

    1. Germany
    2. UK

    Career

    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers

    Information

    1. Events
    2. Information Request
  • Remimazolam

    Sedation & anesthesia market

    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation

    Product Information

    1. About Remimazolam
    2. Clinical trials

    Medical Information

  • Pipeline

    Portfolio

    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA

    Glossary

    1. A_Z
  • Partnering

    Strategy

    1. Partnering strategy
    2. Remimazolam strategy

    Licensing projects

    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board

    Annual general meeting

    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
  • Scientific Hub
<p><a href="http://bethecatalyst.net/" target="_blank"><span class="big">Be the catalyst</span><span class="small">Visit our new Scientific Hub here</span></a></p>

Be the catalystVisit our new Scientific Hub here

prev next
  • Media and Investors  » 
  • Newsroom  » 
  • Press Releases  » 
  • 2008
  • 12/22/2008

    Press release: PAION and ERGOMED complete enrolment of Phase IIa study with CNS 5161 in opioid-refractory cancer pain

    • PDF

  • 12/17/2008

    Press release: PAION's partner Lundbeck initiates clinical phase III trials with Desmoteplase in ischaemic stroke

    • PDF

  • 11/19/2008

    Press release: PAION announces successful completion of Phase I study with the sedative/anaesthetic CNS 7056

    • PDF

  • 11/05/2008

    Press release: PAION AG reports nine-months results 2008

    • PDF

  • 11/03/2008

    Press release: PAION sees improved probability of success for pain drug M6G following successful meta-analysis of clinical data

    • PDF

  • 09/22/2008

    Press release: PAION announces Phase I study with sedative/anaesthetic CNS 7056 progressed to midazolam comparison

    • PDF

  • 08/11/2008

    Press release: PAION AG reports results for the first half-year 2008 and provides strategy update

    • PDF

  • 07/31/2008

    New Supervisory Board Member appointed

    • PDF

  • 07/25/2008

    Press release: PAION announces dosing of first healthy volunteers in Phase I study with its sedative/anaesthetic CNS 7056

    • PDF

  • 07/25/2008

    Regulatory release: Announcement according to Sec 37w WpHG: Publication date for half-year report 2008

    • PDF

  • 07/09/2008

    Press release: PAION announces plan to commence clinical program with its sedative CNS 7056

    • PDF

  • 06/23/2008

    Ad hoc & press release: PAION AG completes acquisition of CeNeS

    • PDF

  • 06/20/2008

    Press release: Court sanctions Scheme of Arrangement for acquisition of CeNeS

    • PDF

  • 05/28/2008

    Press release: shareholders of CeNeS vote for acquisition by PAION

    • PDF

  • 05/21/2008

    PAION's anticoagulant Solulin achieves proof of concept for mode of action in Phase I

    • PDF

  • 05/06/2008

    Press release: PAION Annual General Meeting and CeNeS Acquisition Update

    • PDF

  • 04/29/2008

    Press release: PAION AG reports results for the first quarter 2008

    • PDF

  • 04/23/2008

    Press release: PAION AG acquires world-wide rights to anticoagulant flovagatran from UK company Trigen

    • PDF

  • 04/10/2008

    Ad hoc & press release: PAION AG intends to acquire CeNeS Pharmaceuticals plc

    • PDF

  • 03/03/2008

    Press release: PAION AG reports financial results for fiscal year 2007

    • PDF

  • 02/28/2008

    PAION's anticoagulant Solulin successfully tested in first-in-man study

    • PDF

  • 01/29/2008

    Ad hoc & press release: PAION agreement with Lundbeck comes into force

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Martinstrasse 10-12 | 52062 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Contact +
    1. Germany
    2. UK
  3. Career +
    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers
  4. Information +
    1. Events
    2. Information Request
Remimazolam
  1. Sedation & anesthesia market +
    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation
  2. Product Information +
    1. About Remimazolam
    2. Clinical trials
  3. Medical Information
Pipeline
  1. Portfolio +
    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA
  2. Glossary +
    1. A_Z
Partnering
  1. Strategy +
    1. Partnering strategy
    2. Remimazolam strategy
  2. Licensing projects +
    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
  6. Annual general meeting +
    1. 2021
    2. 2020
    3. 2019
    4. 2018
    5. 2017
    6. 2016
    7. 2015
    8. 2014
    9. 2013
    10. 2012
    11. 2011
    12. 2010
Scientific Hub
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint